Bionano Genomics (MEX:BNGO) ROCE % : -26.15% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Bionano Genomics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bionano Genomics's annualized ROCE % for the quarter that ended in Mar. 2025 was -26.15%.

Bionano Genomics ROCE % Historical Data

The historical data trend for Bionano Genomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics ROCE % Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-139.84

-38.12

-40.41

-108.75

-168.70

Bionano Genomics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-115.74	-70.75	-251.97	-177.27	-26.15

Bionano Genomics ROCE % Calculation

Bionano Genomics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-2329.477	/	( ( (3639.347 - 1697.9)	+	(1599.007 - 778.835) )	/ 2 )
	=	-2329.477	/	( (1941.447	+	820.172)	/ 2 )
	=	-2329.477	/	1380.8095
	=	-168.70 %

Bionano Genomics's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-246.316	/	( ( (1599.007 - 778.835)	+	(1604.209 - 540.26) )	/ 2 )
	=	-246.316	/	( ( 820.172	+	1063.949 )	/ 2 )
	=	-246.316	/	942.0605
	=	-26.15 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Bionano Genomics (MEX:BNGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bionano Genomics ROCE % Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BNGO:USA

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.